RU2007132852A - Продукт комбинации о-десметилвенлафаксина и базедоксифена и его применение - Google Patents
Продукт комбинации о-десметилвенлафаксина и базедоксифена и его применение Download PDFInfo
- Publication number
- RU2007132852A RU2007132852A RU2007132852/15A RU2007132852A RU2007132852A RU 2007132852 A RU2007132852 A RU 2007132852A RU 2007132852/15 A RU2007132852/15 A RU 2007132852/15A RU 2007132852 A RU2007132852 A RU 2007132852A RU 2007132852 A RU2007132852 A RU 2007132852A
- Authority
- RU
- Russia
- Prior art keywords
- bazedoxifene
- product according
- pharmaceutically acceptable
- acceptable salt
- desmethylvenlafaxine
- Prior art date
Links
- 239000013066 combination product Substances 0.000 title claims 4
- 229940127555 combination product Drugs 0.000 title claims 4
- 229960000817 bazedoxifene Drugs 0.000 claims abstract 22
- UCJGJABZCDBEDK-UHFFFAOYSA-N bazedoxifene Chemical compound C=1C=C(OCCN2CCCCCC2)C=CC=1CN1C2=CC=C(O)C=C2C(C)=C1C1=CC=C(O)C=C1 UCJGJABZCDBEDK-UHFFFAOYSA-N 0.000 claims abstract 22
- 150000003839 salts Chemical class 0.000 claims abstract 19
- ORUUBRMVQCKYHB-UHFFFAOYSA-N butanedioic acid;4-[2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]phenol Chemical compound OC(=O)CCC(O)=O.C1CCCCC1(O)C(CN(C)C)C1=CC=C(O)C=C1 ORUUBRMVQCKYHB-UHFFFAOYSA-N 0.000 claims abstract 13
- KYYIDSXMWOZKMP-UHFFFAOYSA-N O-desmethylvenlafaxine Chemical compound C1CCCCC1(O)C(CN(C)C)C1=CC=C(O)C=C1 KYYIDSXMWOZKMP-UHFFFAOYSA-N 0.000 claims abstract 11
- 239000010410 layer Substances 0.000 claims abstract 11
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims abstract 10
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract 7
- OMZAMQFQZMUNTP-UHFFFAOYSA-N acetic acid;1-[[4-[2-(azepan-1-yl)ethoxy]phenyl]methyl]-2-(4-hydroxyphenyl)-3-methylindol-5-ol Chemical compound CC(O)=O.C=1C=C(OCCN2CCCCCC2)C=CC=1CN1C2=CC=C(O)C=C2C(C)=C1C1=CC=C(O)C=C1 OMZAMQFQZMUNTP-UHFFFAOYSA-N 0.000 claims abstract 7
- 229960003713 bazedoxifene acetate Drugs 0.000 claims abstract 7
- 239000002775 capsule Substances 0.000 claims abstract 7
- 229960004981 desvenlafaxine succinate Drugs 0.000 claims abstract 7
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract 7
- 239000008108 microcrystalline cellulose Substances 0.000 claims abstract 7
- 229940016286 microcrystalline cellulose Drugs 0.000 claims abstract 7
- 235000019359 magnesium stearate Nutrition 0.000 claims abstract 5
- 239000011247 coating layer Substances 0.000 claims abstract 4
- 150000001875 compounds Chemical class 0.000 claims abstract 4
- 239000012458 free base Substances 0.000 claims abstract 4
- 239000000454 talc Substances 0.000 claims abstract 3
- 229910052623 talc Inorganic materials 0.000 claims abstract 3
- 235000012222 talc Nutrition 0.000 claims abstract 2
- 239000000047 product Substances 0.000 claims 17
- 239000003814 drug Substances 0.000 claims 6
- 238000004519 manufacturing process Methods 0.000 claims 6
- 208000019901 Anxiety disease Diseases 0.000 claims 5
- 206010003694 Atrophy Diseases 0.000 claims 5
- 208000001640 Fibromyalgia Diseases 0.000 claims 5
- 208000033830 Hot Flashes Diseases 0.000 claims 5
- 206010060800 Hot flush Diseases 0.000 claims 5
- 208000001132 Osteoporosis Diseases 0.000 claims 5
- 206010066218 Stress Urinary Incontinence Diseases 0.000 claims 5
- 230000036506 anxiety Effects 0.000 claims 5
- 230000037444 atrophy Effects 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 229940011871 estrogen Drugs 0.000 claims 5
- 239000000262 estrogen Substances 0.000 claims 5
- 230000000968 intestinal effect Effects 0.000 claims 5
- 230000035945 sensitivity Effects 0.000 claims 5
- 239000007962 solid dispersion Substances 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 4
- 239000008187 granular material Substances 0.000 claims 4
- 238000000034 method Methods 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 2
- 239000008101 lactose Substances 0.000 claims 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 1
- 229920002785 Croscarmellose sodium Polymers 0.000 claims 1
- 208000020401 Depressive disease Diseases 0.000 claims 1
- 229920000881 Modified starch Polymers 0.000 claims 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims 1
- 229920002472 Starch Polymers 0.000 claims 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 1
- 229960005070 ascorbic acid Drugs 0.000 claims 1
- 235000010323 ascorbic acid Nutrition 0.000 claims 1
- 239000011668 ascorbic acid Substances 0.000 claims 1
- 239000011248 coating agent Substances 0.000 claims 1
- 238000000576 coating method Methods 0.000 claims 1
- 229960001681 croscarmellose sodium Drugs 0.000 claims 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 229960001375 lactose Drugs 0.000 claims 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- 239000000377 silicon dioxide Substances 0.000 claims 1
- 235000012239 silicon dioxide Nutrition 0.000 claims 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims 1
- 229920003109 sodium starch glycolate Polymers 0.000 claims 1
- 229940079832 sodium starch glycolate Drugs 0.000 claims 1
- 239000008109 sodium starch glycolate Substances 0.000 claims 1
- 229940032147 starch Drugs 0.000 claims 1
- 235000019698 starch Nutrition 0.000 claims 1
- 239000008107 starch Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C215/64—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US66690205P | 2005-03-31 | 2005-03-31 | |
| US60/666,902 | 2005-03-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2007132852A true RU2007132852A (ru) | 2009-05-10 |
Family
ID=36716648
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2007132852/15A RU2007132852A (ru) | 2005-03-31 | 2006-03-22 | Продукт комбинации о-десметилвенлафаксина и базедоксифена и его применение |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US20060223791A1 (enExample) |
| EP (1) | EP1863464B1 (enExample) |
| JP (1) | JP2008534592A (enExample) |
| KR (1) | KR20070116607A (enExample) |
| CN (1) | CN101151026A (enExample) |
| AR (1) | AR052955A1 (enExample) |
| AT (1) | ATE447943T1 (enExample) |
| AU (1) | AU2006229869A1 (enExample) |
| BR (1) | BRPI0608754A2 (enExample) |
| CA (1) | CA2601898A1 (enExample) |
| CR (1) | CR9392A (enExample) |
| DE (1) | DE602006010343D1 (enExample) |
| ES (1) | ES2335919T3 (enExample) |
| GT (1) | GT200600127A (enExample) |
| IL (1) | IL185864A0 (enExample) |
| MX (1) | MX2007012167A (enExample) |
| NO (1) | NO20074559L (enExample) |
| PE (1) | PE20061336A1 (enExample) |
| RU (1) | RU2007132852A (enExample) |
| TW (1) | TW200719883A (enExample) |
| WO (1) | WO2006104791A1 (enExample) |
| ZA (1) | ZA200708323B (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GT200500083A (es) * | 2004-04-08 | 2005-10-31 | Formulaciones de acetato de bazedoxifeno | |
| US7595340B2 (en) * | 2005-07-15 | 2009-09-29 | Wyeth | Serotonin and norepinephrine reuptake inhibitor and uses thereof |
| US7687520B2 (en) * | 2005-07-15 | 2010-03-30 | Wyeth Llc | Serotonin and norepinephrine reuptake inhibitors and uses thereof |
| EP1904434A2 (en) * | 2005-07-15 | 2008-04-02 | Wyeth a Corporation of the State of Delaware | Highly selective serotonin and norepinephrine dual reuptake inhibitor and use thereof |
| TW200806282A (en) * | 2006-05-05 | 2008-02-01 | Wyeth Corp | Solid dosage formulations |
| JP2010511062A (ja) * | 2006-11-29 | 2010-04-08 | ワイス エルエルシー | エストロゲン／ｓｅｒｍおよびエストロゲン／プロゲスチン二層錠剤 |
| US20100210719A1 (en) * | 2007-07-12 | 2010-08-19 | Dr. Reddy's Laboratories Ltd. | O-desmethylvenlafaxine |
| CZ302358B6 (cs) * | 2007-07-25 | 2011-03-30 | Zentiva, A. S. | Nové soli bazedoxifenu |
| CN101584696A (zh) * | 2008-05-21 | 2009-11-25 | 上海艾力斯医药科技有限公司 | 包含喹唑啉衍生物的组合物及制备方法、用途 |
| EP2552419A2 (en) * | 2010-03-31 | 2013-02-06 | Wockhardt Limited | Modified release dosage form comprising desvenlafaxine or salts thereof |
| EP2407467A1 (de) * | 2010-07-14 | 2012-01-18 | Sandoz Ag | Kristalline Verbindung von 1-[4-(2-azepan-1-yl-ethoxy)-benzyl]-2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol und Milchsäure |
| WO2012140577A1 (en) * | 2011-04-12 | 2012-10-18 | Lupin Limited | Modified release pharmaceutical compositions of desvenlafaxine |
| WO2013182170A1 (en) * | 2012-06-07 | 2013-12-12 | Zentiva, K. S. | Enhancement of dissolution rate from pharmaceutical composition comprising bazedoxifene acetate |
| CN112754999A (zh) * | 2021-01-23 | 2021-05-07 | 郑州泰丰制药有限公司 | 一种醋酸巴多昔芬组合物及醋酸巴多昔芬薄膜衣片制备方法 |
| CN113368075A (zh) * | 2021-06-29 | 2021-09-10 | 郑州泰丰制药有限公司 | 一种醋酸巴多昔芬片及其制备方法 |
| CN120531695A (zh) * | 2023-08-03 | 2025-08-26 | 常山凯捷健生物药物研发（河北）有限公司 | 一种包含取代的吲哚-5-酚衍生物的药物组合物及其应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4535186A (en) * | 1983-04-19 | 1985-08-13 | American Home Products Corporation | 2-Phenyl-2-(1-hydroxycycloalkyl or 1-hydroxycycloalk-2-enyl)ethylamine derivatives |
| US5998402A (en) * | 1996-04-19 | 1999-12-07 | American Home Products Corporation | 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents |
| US6479535B1 (en) * | 1998-05-15 | 2002-11-12 | Wyeth | 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations |
| JP2004502729A (ja) * | 2000-07-06 | 2004-01-29 | ワイス | Ｓｓｒｉおよびエストロゲン剤の組み合わせ |
| AR029538A1 (es) * | 2000-07-06 | 2003-07-02 | Wyeth Corp | Composiciones farmaceuticas de agentes estrogenicos |
| EA011451B1 (ru) * | 2001-02-12 | 2009-04-28 | Уайт | Новая соль сукцинат о-десметилвенлафаксина |
| RU2355397C2 (ru) * | 2002-06-13 | 2009-05-20 | Уайт | Режимы лечения базедоксифеном |
| WO2005077340A1 (en) * | 2004-02-06 | 2005-08-25 | Wyeth | Multiparticulate o-desmethylvenlafaxine salts and uses thereof |
| TW200740427A (en) * | 2005-07-15 | 2007-11-01 | Wyeth Corp | Highly bioavailable oral delayed release dosage forms of O-desmethylvenlafaxine succinate |
-
2006
- 2006-03-22 ES ES06739215T patent/ES2335919T3/es not_active Expired - Lifetime
- 2006-03-22 KR KR1020077021609A patent/KR20070116607A/ko not_active Withdrawn
- 2006-03-22 RU RU2007132852/15A patent/RU2007132852A/ru not_active Application Discontinuation
- 2006-03-22 BR BRPI0608754-0A patent/BRPI0608754A2/pt not_active IP Right Cessation
- 2006-03-22 AU AU2006229869A patent/AU2006229869A1/en not_active Abandoned
- 2006-03-22 DE DE602006010343T patent/DE602006010343D1/de not_active Expired - Lifetime
- 2006-03-22 US US11/386,420 patent/US20060223791A1/en not_active Abandoned
- 2006-03-22 MX MX2007012167A patent/MX2007012167A/es active IP Right Grant
- 2006-03-22 CN CNA2006800102992A patent/CN101151026A/zh active Pending
- 2006-03-22 CA CA002601898A patent/CA2601898A1/en not_active Abandoned
- 2006-03-22 WO PCT/US2006/010335 patent/WO2006104791A1/en not_active Ceased
- 2006-03-22 EP EP06739215A patent/EP1863464B1/en not_active Expired - Lifetime
- 2006-03-22 JP JP2008504152A patent/JP2008534592A/ja not_active Withdrawn
- 2006-03-22 AT AT06739215T patent/ATE447943T1/de not_active IP Right Cessation
- 2006-03-27 TW TW095110550A patent/TW200719883A/zh unknown
- 2006-03-29 GT GT200600127A patent/GT200600127A/es unknown
- 2006-03-29 AR ARP060101219A patent/AR052955A1/es unknown
- 2006-03-29 PE PE2006000349A patent/PE20061336A1/es not_active Application Discontinuation
-
2007
- 2007-09-10 IL IL185864A patent/IL185864A0/en unknown
- 2007-09-10 NO NO20074559A patent/NO20074559L/no not_active Application Discontinuation
- 2007-09-24 CR CR9392A patent/CR9392A/es not_active Application Discontinuation
- 2007-09-28 ZA ZA200708323A patent/ZA200708323B/xx unknown
-
2010
- 2010-04-30 US US12/771,350 patent/US20100221445A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MX2007012167A (es) | 2007-11-22 |
| ZA200708323B (en) | 2010-03-31 |
| PE20061336A1 (es) | 2006-12-27 |
| TW200719883A (en) | 2007-06-01 |
| JP2008534592A (ja) | 2008-08-28 |
| US20100221445A1 (en) | 2010-09-02 |
| US20060223791A1 (en) | 2006-10-05 |
| EP1863464B1 (en) | 2009-11-11 |
| KR20070116607A (ko) | 2007-12-10 |
| ATE447943T1 (de) | 2009-11-15 |
| CN101151026A (zh) | 2008-03-26 |
| GT200600127A (es) | 2006-11-29 |
| WO2006104791A1 (en) | 2006-10-05 |
| CR9392A (es) | 2008-02-20 |
| CA2601898A1 (en) | 2006-10-05 |
| EP1863464A1 (en) | 2007-12-12 |
| IL185864A0 (en) | 2008-01-06 |
| DE602006010343D1 (de) | 2009-12-24 |
| AR052955A1 (es) | 2007-04-11 |
| ES2335919T3 (es) | 2010-04-06 |
| AU2006229869A1 (en) | 2006-10-05 |
| BRPI0608754A2 (pt) | 2010-01-26 |
| NO20074559L (no) | 2007-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9901568B2 (en) | Pharmaceutical compositions of 5-hydroxytryptophan and serotonin-enhancing compound | |
| JP5656883B2 (ja) | エスゾピクロンを用いる治療方法 | |
| CN120040398A (zh) | 用于精神障碍或精神增强的有利苯并呋喃组合物 | |
| CN116096715A (zh) | 用于精神障碍或精神增强的有益苯并噻吩组合物 | |
| JP2014205697A (ja) | ゾニサミドおよびアカンプロセートを用いるアルツハイマー病および関連障害の処置のための併用組成物 | |
| CN116209657A (zh) | 用于精神障碍或增强的2-氨基茚满化合物 | |
| CA2829200C (en) | Methods and compositions for treating depression using cyclobenzaprine | |
| JP2008534592A5 (enExample) | ||
| WO2018193648A1 (ja) | アルカリ性化剤による血液浄化 | |
| MX2008000249A (es) | Combinaciones de eszopiclona y o-desmetilvenlafaxina y metodos de tratamiento de menopausia y trastornos del estado de animo, ansiedad y cognitivos. | |
| CA2614244A1 (en) | Combinations of eszopiclone and an antidepressant | |
| US7465729B2 (en) | Methods of treatment of menopause and perimenopause using eszopiclone | |
| KR20200128437A (ko) | 치료 방법 | |
| CN110251473A (zh) | 羟哌吡酮口服缓释制剂 | |
| JP2010024244A (ja) | 処置方法 | |
| US20150157682A1 (en) | Valerian extracts and uses thereof | |
| WO2006065555A2 (en) | Use of alpha-adrenergic blockers for the treatment of dysmenorrhea | |
| CN111035763A (zh) | 一种治疗妇女更年期综合症的药物组合物 | |
| AU2011202540B2 (en) | Methods of treatment using eszopiclone | |
| CN101596195A (zh) | 降低血压的口服药物组合物 | |
| CA2425910A1 (en) | Treatment and prevention of gastrointestinal disease using antagonists or partial agonists of 5ht1a receptors | |
| CA2912302A1 (en) | Compositions and methods for treating cardiometabolic diseases and disorders | |
| TH1901003565A (th) | รูปที่ใช้โดสทางปากที่มีการปลดปล่อยในทันทีและที่ถูกดัดแปรของทีไบพีเนม พิโวซิลชนิดใหม่ | |
| NZ714294B2 (en) | Methods And Compositions For Treating Depression Using Cyclobenzaprine | |
| HK1073779B (en) | The use of darifenacin and the salt thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA94 | Acknowledgement of application withdrawn (non-payment of fees) |
Effective date: 20110516 |